Polymyositis and Dermatomyositis
The most likely autoimmune cause of pain and weakness in the hand muscles is polymyositis (PM) or dermatomyositis (DM), which are idiopathic inflammatory myopathies (IIMs) characterized by symmetric proximal muscle weakness that can extend to distal muscles including the hands. 1
Key Clinical Features
The idiopathic inflammatory myopathies present with:
- Symmetric proximal muscle weakness developing over weeks to months, though distal hand involvement occurs
- Elevated muscle enzymes (CK levels often significantly elevated)
- Muscle pain accompanying the weakness
- Extramuscular manifestations including fever, weight loss, and in dermatomyositis, characteristic skin findings 1
Distinguishing Between IIM Subtypes
Dermatomyositis is identified by:
- Erythematous, photosensitive rash with Gottron papules
- Heliotrope rash and periorbital edema
- Periungual telangiectasias
- Proximal muscle weakness with hand involvement 1
Polymyositis presents with:
- Symmetric proximal muscle weakness without the characteristic DM rash
- CD8+ cytotoxic T cells invading nonnecrotic muscle fibers on biopsy
- Similar pattern of muscle involvement including hands 1
Important Differential: Inclusion Body Myositis
A critical pitfall to avoid: Sporadic inclusion body myositis (sIBM) distinctively affects the hands but has a different pattern. It presents with:
- Asymmetric weakness involving finger flexors and forearm flexors specifically
- Atrophy of forearm flexors, finger flexors, and quadriceps
- Onset after age 50 years with 3:1 male predominance
- Poor response to immunosuppression (unlike PM/DM) 1
This is crucial because sIBM requires different management expectations and has degenerative features analogous to Alzheimer disease with rimmed vacuoles on biopsy 1.
Diagnostic Approach
The 2017 EULAR/ACR classification criteria provide a probability-based scoring system requiring:
- Minimum probability of 55% (score ≥5.5 without biopsy; ≥6.7 with biopsy) for "probable IIM"
- ≥90% probability (score ≥7.5 without biopsy; ≥8.7 with biopsy) for "definite IIM" 2
Essential Workup Elements
Look specifically for:
- Muscle enzyme elevations (CK, aldolase, LDH)
- EMG findings: polyphasic motor unit potentials, fibrillation potentials, sharp waves
- MRI of proximal muscles: T2-weighted sequences with fat suppression showing muscle inflammation
- Myositis-specific autoantibodies: define subgroups and predict prognosis
- Muscle biopsy: endomysial mononuclear inflammatory infiltrate 1
Other Autoimmune Considerations
While less likely to primarily present as hand muscle pain and weakness:
Systemic sclerosis causes hand impairment through multiple mechanisms including inflammatory arthritis, but is typically recognized first by Raynaud's phenomenon, puffy hands, and skin thickening rather than primary muscle weakness 3
Systemic lupus erythematosus causes hand problems predominantly through arthritis, reduced grip force, and activity-induced pain rather than true muscle weakness 4
Management Implications
For newly diagnosed uncomplicated IIM, initiate:
- High-dose corticosteroids (prednisone 1 mg/kg/day, maximum 60-80 mg/day)
- Concurrent steroid-sparing agent from onset: methotrexate, azathioprine, or mycophenolate mofetil
- Taper corticosteroids after clinical response 1
For severe disease or refractory cases:
- High-dose IV methylprednisolone
- Add intravenous immunoglobulin (IVIG), cyclophosphamide, rituximab, or cyclosporine 1
The concurrent initiation of steroid-sparing agents is critical to minimize long-term corticosteroid complications including corticosteroid-induced myopathy, which can confound the clinical picture 1.